ENTX earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -7.71. Updated 2026-07-23.
Entera Bio (ENTX) Research Hub
Entera Bio (ENTX) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.84 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.71, market cap 0.10B. This hub links to the full technical, earnings and options research available for ENTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 2.84 USD (0.00%) |
| 52-week range | 1.16 USD – 3.96 USD |
| Trend regime | Range |
| 14-day RSI | 49.1 (Neutral) |
| Trailing P/E | -7.71 |
| Market cap | 0.10B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for ENTX
Covered Call on ENTX: how it works, illustrative setup around the real 2.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENTX: how it works, illustrative setup around the real 2.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENTX: how it works, illustrative setup around the real 2.84 USD price, max profit/loss, breakeven and when to use it. Educational.
ENTX technical analysis: range, last 2.84 USD, RSI 49.1, 52w range 1.16 USD–3.96 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENTX in?
Entera Bio (ENTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is ENTX in an uptrend or downtrend?
As of 2026-09-11, ENTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENTX's trailing P/E ratio?
ENTX's trailing P/E is -7.71, with a market cap of 0.10B. See the earnings research page for full valuation detail.
When does ENTX next report earnings?
ENTX is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.08 USD.